Business highlights

210
Products
(15 originals and 195 generics)
15
production facilities
400
partners
The three Sopharma AD factories - the one in Kazanlak, the Tablet production and Ampoule production in...
Nivalin
Financial News
25 September 2017
Bulgarian Stock Exchange
Warsaw Stock Exchange
Whatever is good for our people is good for us.

Financial highlights

877,085
BGN '000 Revenues 2016
73,656
BGN '000 EBITDA 2016
What we do
Developing, manufacturing and delivering accessible treatment to millions of people.
Developing, manufacturing and delivering accessible treatment to millions of people.
We are a leading producer and distributor of health related products. Our business model is vertically integrated running through the whole value chain.
Our heritage
Contributing to the history of healthcare in Bulgaria.
Our heritage
Contributing to the history of healthcare in Bulgaria.
As part of the national economic system we have closely followed the developments and turnarounds of our country, pursuing as a human mission high standards of quality, safety and efficiency of medication and spreading health culture while enhancing sector performances and achievements.
Looking ahead
Becoming a strong regional player and the first partnering choice.
Looking ahead
Becoming a strong regional player and the first partnering choice.
A solid and long-lasting financial strategy based on profitability sustainable development and on strong performance in key markets. We are building a business strategy focused on diversification and expansion, in order to become the best and most attractive investment choice for our stakeholders.